

To improve the lives of patients by creating & developing innovative antibody products



Foundational Products: Solid Financial Base, Significant potential

DARZALEX[®], Arzerra[®], ofatumumab [RMS]



Our Own Clinical Pipeline Potential first-in-class / Best-in-class

Tisotumab vedotin, enapotamab vedotin, HexaBody[®]-DR5/DR5, DuoBody[®]-CD3xCD20



2019 Projected INDs/CTAs Accelerating Growth

DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, DuoHexaBody[®]-CD37



Technologies & Pre-Clinical R&D Engine: Powerhouse of Innovation

DuoBody, HexaBody, DuoHexaBody, HexElect[®] platforms & rich-pre-clinical pipeline



Our Three-pronged Strategy

- Focus on core competence
- Turn science into medicine
 - Build a profitable & successful biotech



Our Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies



Proprietary technologies allow us to build world-class pipeline



Deep insight into antibody biology & disease targets



Match in-house expertise with strategic partnerships



Strong pipeline of first-in-class / best-in-class products

2019 Guidance Income Statement

	DKKM	USDM ²
Revenue	4,600	767
Operating expenses	(2,600)	(433)
Operating income	2,000	333

²USD 1.00 = DKK 6.00

DKK

66B

~USD 10B¹

2018 year end market cap

DKK

3,025M

~USD 464M¹

2018 revenue 28% increase vs 2017

DKK

1,645M

~USD 252M¹

2018 operating expenses
87% invested in R&D

DKK


6,106M

~USD 936M¹

2018 year end cash position

Revenue

MDKK (~MUSD¹)



¹USD 1.00 = DKK 6.5213

Innovation Powerhouse

Genmab Proprietary Products and innovative Pre-clinical Pipeline

Product	Disease Indications	Most Advanced Dev. Phase						
		Pre-Clin	I	I/II	II	III	Launch	
Tisotumab vedotin Target: TF / Partner: Seattle Genetics	Cervical cancer							
	Ovarian cancer							
	Solid tumors							
Enapotamab vedotin Target: AXL	Solid tumors							
HexaBody-DR5/DR5 Target: DR5	Solid tumors							
DuoBody-CD3xCD20 Targets: CD3, CD20	Hematological malignancies							
DuoBody-PD-L1x4-1BB* Targets: PD-L1, 4-1BB / Partner: BioNTech	Solid tumors							
IND / CTA expected in 2019	DuoHexaBody-CD37							
Marketed Products								
Daratumumab Target: CD38 / Partner: Janssen	MM ³							
	AL Amyloidosis							
	Non-MM blood cancers							
Ofatumumab Target: CD20 / Partner Novartis	CLL ³							
	RMS							
Partner Programs								
Teprotumumab Target: IGF-1R / Partner: Horizon Pharma	Thyroid eye disease							
HuMax-IL8 Target: IL8 / Partner: BMS	Advanced cancers							
Camidanlumab tesirine Target: CD25 / Partner: ADCT	Lymphoma							
	Solid tumors							
JNJ-61186372 Targets: EGFR, cMet / Partner: Janssen	NSCLC							
JNJ-63709178 Targets: CD123, CD3 / Partner: Janssen	Acute Myeloid Leukemia (AML)							
JNJ-64007957 Targets: BCMA, CD3 / Partner: Janssen	Relapsed or refractory MM							
JNJ-64407564 Targets: GPRC5D, CD3 / Partner: Janssen	Relapsed or refractory MM							
JNJ-67571244 Targets: CD33, CD3 / Partner: Janssen	AML							
JNJ-63898081* Partner: Janssen	Solid tumors							
Lu AF82422 Target: alfa-Synuclein Partner: Lundbeck	Parkinson's disease							
Partnered programs	HuMab & DuoBody							

*announced

PRODUCTS & TECHNOLOGIES

Tisotumab vedotin

- Antibody-drug conjugate (ADC) in dev. to treat solid tumors
- Ph. II potential reg. study in cervical cancer
- Ph II studies in ovarian & other solid tumors
- 50:50 agreement w/ Seattle Genetics

Enapotamab vedotin

- ADC in development to treat solid tumors
- Ph I/II clinical study for multiple solid tumors

HexaBody-DR5/DR5

- Proprietary antibody therapeutic created w/ Genmab's HexaBody technology
- Phase I/II clinical trial in solid tumors

DuoBody-CD3xCD20

- Proprietary bispecific antibody created w/ Genmab's DuoBody technology
- Phase I/II clinical trial in B-cell malignancies

DuoBody-PD-L1x4-1BB

- Proprietary bispecific antibody created w/ Genmab's DuoBody technology
- Phase I/II clinical trial in solid tumors announced
- 50:50 agreement w/ BioNTech

DuoBody-CD40x4-1BB

- Proprietary bispecific antibody created w/ Genmab's DuoBody technology
- First CTA filed in March 2019
- 50:50 agreement w/ BioNTech

DARZALEX (daratumumab)

- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications³
- Multiple Ph III studies ongoing in MM, amyloidosis & SubQ formulation
- Collaboration w/ Janssen
- 2018 net sales by Janssen: \$2,025M

Executive Management:

Jan G. J. van de Winkel, Ph.D. President & CEO
David A. Eatwell FCCA, EVP & CFO
Judith Klimovsky M.D., EVP & CDO

Founded: 1999, IPO: 2000

Exchange: NASDAQ

Arzerra (ofatumumab)

- Human CD20 monoclonal antibody developed in collaboration w/ Novartis
- Approved in certain territories for various chronic lymphocytic leukemia (CLL) indications³
- 2018 net sales by Novartis: \$26M

Ofatumumab (OMB157)

- SubQ formulation in development to treat relapsing multiple sclerosis (RMS)
- Recruitment completed in 2 Ph. III studies in RMS

DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform

- Antibody technology that combines DuoBody & HexaBody platforms
- Creates bispecific antibodies w/ target-mediated enhanced potency

HexElect Platform

- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting w/ enhanced selectivity & potency

³See local country prescribing information for precise indications

Symbol: GEN

ADR ticker Symbol: GMXY

Stock information as of May 8, 2019

Market cap: ~DKK 69 Bn (~USD 10,337 M)

Shares outstanding: 61,670,829